Non-alcoholic fatty liver DISEASE (NAFLD) is the most common chronic liver disease in
Western countries and affects approximately 25% of the adult population. Since NAFLD is …

Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized public health
problem, affecting up to a quarter of the world's adult population. The burden of NAFLD is …

This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document …

Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic fat
accumulation after the exclusion of other causes of hepatic steatosis, including other causes …

Key physiological functions of the liver, including glucose and lipid metabolism, become
disturbed in the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated …

Background & Aims Non-alcoholic fatty liver disease (NAFLD) is very common in the general
population, but identifying patients with increased risk of mortality and liver-specific morbidity …

Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease that
occurs in the setting of insulin resistance and increased adiposity. It has rapidly evolved into …

Non-alcoholic fatty liver disease (NAFLD) has become one of the most common forms of
chronic liver disease worldwide and its prevalence is expected to continue rising. NAFLD …

Nonalcoholic fatty liver disease (NAFLD) affects around a quarter of the global population,
paralleling worldwide increases in obesity and metabolic syndrome. NAFLD arises in the …

Inhibition of apoptosis signal–regulating kinase 1, a serine/threonine kinase, leads to
improvement in inflammation and fibrosis in animal models of nonalcoholic steatohepatitis …